Biomedical Applications of Iron Oxide Nanoparticles: Current Insights Progress and Perspectives

Schneider, María Gabriela Montiel; Martín, María Julia; Otarola, Jessica; Vakarelska, Ekaterina; Simeonov, Vasil; Lassalle, Verónica Leticia; Nedyalkova, Miroslava

doi:10.3390/pharmaceutics14010204

Cited by 155 publications

(75 citation statements)

References 145 publications

(173 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, their specificity against cancer cells can be increased by adding molecular targeting moieties (antibodies/peptides, etc.) in their structures [ 5 , 6 , 7 ]. More recently, NPs have been investigated as nanobrachytherapy agents after intratumoral injection [ 8 , 9 , 10 , 11 , 12 ].…”

Section: Introductionmentioning

confidence: 99%

Preliminary Evaluation of Iron Oxide Nanoparticles Radiolabeled with 68Ga and 177Lu as Potential Theranostic Agents

et al. 2022

View full text Add to dashboard Cite

Theranostic radioisotope pairs such as Gallium-68 (68Ga) for Positron Emission Tomography (PET) and Lutetium-177 (177Lu) for radioisotopic therapy, in conjunction with nanoparticles (NPs), are an emerging field in the treatment of cancer. The present work aims to demonstrate the ability of condensed colloidal nanocrystal clusters (co-CNCs) comprised of iron oxide nanoparticles, coated with alginic acid (MA) and stabilized by a layer of polyethylene glycol (MAPEG) to be directly radiolabeled with 68Ga and its therapeutic analog 177Lu. 68Ga/177Lu- MA and MAPEG were investigated for their in vitro stability. The biocompatibility of the non-radiolabeled nanoparticles, as well as the cytotoxicity of MA, MAPEG, and [177Lu]Lu-MAPEG were assessed on 4T1 cells. Finally, the ex vivo biodistribution of the 68Ga-labeled NPs as well as [177Lu]Lu-MAPEG was investigated in normal mice. Radiolabeling with both radioisotopes took place via a simple and direct labelling method without further purification. Hemocompatibility was verified for both NPs, while MTT studies demonstrated the non-cytotoxic profile of the nanocarriers and the dose-dependent toxicity for [177Lu]Lu-MAPEG. The radiolabeled nanoparticles mainly accumulated in RES organs. Based on our preliminary results, we conclude that MAPEG could be further investigated as a theranostic agent for PET diagnosis and therapy of cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Preliminary Evaluation of Iron Oxide Nanoparticles Radiolabeled with 68Ga and 177Lu as Potential Theranostic Agents

et al. 2022

View full text Add to dashboard Cite

show abstract

“… 168 IONPs have been studied for their potential use in cancer treatment. 169 One of the most promising applications is magnetic hyperthermia, which involves heating cancer cells using an alternating magnetic field to generate heat within the NPs. 170 This heat can damage or kill the cancer cells while minimizing harm to healthy tissue.…”

Section: Applications Of Metal‐based Nms In Different Types Of Cancermentioning

confidence: 99%

Metal‐based nanomaterials and nanocomposites as promising frontier in cancer chemotherapy

Kumar

Shukla

Sharma

et al. 2023

MedComm

View full text Add to dashboard Cite

Cancer is a disease associated with complex pathology and one of the most prevalent and leading reasons for mortality in the world. Current chemotherapy has challenges with cytotoxicity, selectivity, multidrug resistance, and the formation of stemlike cells. Nanomaterials (NMs) have unique properties that make them useful for various diagnostic and therapeutic purposes in cancer research. NMs can be engineered to target cancer cells for early detection and can deliver drugs directly to cancer cells, reducing side effects and improving treatment efficacy. Several of NMs can also be used for photothermal therapy to destroy cancer cells or enhance immune response to cancer by delivering immune‐stimulating molecules to immune cells or modulating the tumor microenvironment. NMs are being modified to overcome issues, such as toxicity, lack of selectivity, increase drug capacity, and bioavailability, for a wide spectrum of cancer therapies. To improve targeted drug delivery using nano‐carriers, noteworthy research is required. Several metal‐based NMs have been studied with the expectation of finding a cure for cancer treatment. In this review, the current development and the potential of plant and metal‐based NMs with their effects on size and shape have been discussed along with their more effective usage in cancer diagnosis and treatment.

show abstract

“…The iron oxide NP’s biocompatibility is assured by natural occurrence in human cells and a remarkable advantage of possible neosynthesis in cellulo [ 20 ]. In general, they possess acceptable biocompatibility and stability; however, they are restricted for some clinical applications due to low solubility and toxicity effects [ 21 ]. Importantly, the magnetocalorimetric properties of the iron oxide NPs, namely, the ability to induce heating by magnetic hyperthermia (MHT) and photothermia (PT) [ 22 ], can be exploited for sensitization to TRAIL-dependent cell death.…”

Section: Inorganic Nanoparticles Modified With Trail Pathway-targetin...mentioning

confidence: 99%

Recent Advances in the Development of Nanodelivery Systems Targeting the TRAIL Death Receptor Pathway

2023

View full text Add to dashboard Cite

The TRAIL (TNF-related apoptosis-inducing ligand) apoptotic pathway is extensively exploited in the development of targeted antitumor therapy due to TRAIL specificity towards its cognate receptors, namely death receptors DR4 and DR5. Although therapies targeting the TRAIL pathway have encountered many obstacles in attempts at clinical implementation for cancer treatment, the unique features of the TRAIL signaling pathway continue to attract the attention of researchers. Special attention is paid to the design of novel nanoscaled delivery systems, primarily aimed at increasing the valency of the ligand for improved death receptor clustering that enhances apoptotic signaling. Optionally, complex nanoformulations can allow the encapsulation of several therapeutic molecules for a combined synergistic effect, for example, chemotherapeutic agents or photosensitizers. Scaffolds for the developed nanodelivery systems are fabricated by a wide range of conventional clinically approved materials and innovative ones, including metals, carbon, lipids, polymers, nanogels, protein nanocages, virus-based nanoparticles, dendrimers, DNA origami nanostructures, and their complex combinations. Most nanotherapeutics targeting the TRAIL pathway are aimed at tumor therapy and theranostics. However, given the wide spectrum of action of TRAIL due to its natural role in immune system homeostasis, other therapeutic areas are also involved, such as liver fibrosis, rheumatoid arthritis, Alzheimer’s disease, and inflammatory diseases caused by bacterial infections. This review summarizes the recent innovative developments in the design of nanodelivery systems modified with TRAIL pathway-targeting ligands.

show abstract

Biomedical Applications of Iron Oxide Nanoparticles: Current Insights Progress and Perspectives

Cited by 155 publications

References 145 publications

Preliminary Evaluation of Iron Oxide Nanoparticles Radiolabeled with 68Ga and 177Lu as Potential Theranostic Agents

Preliminary Evaluation of Iron Oxide Nanoparticles Radiolabeled with 68Ga and 177Lu as Potential Theranostic Agents

Metal‐based nanomaterials and nanocomposites as promising frontier in cancer chemotherapy

Recent Advances in the Development of Nanodelivery Systems Targeting the TRAIL Death Receptor Pathway

Contact Info

Product

Resources

About